Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
Identifieur interne : 000A44 ( Main/Exploration ); précédent : 000A43; suivant : 000A45Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
Auteurs : John M. Woulfe [Canada] ; Madison T. Gray [Canada] ; Douglas A. Gray [Canada] ; David G. Munoz [Canada] ; Jaap M. Middeldorp [Pays-Bas]Source :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- genetics : Parkinson Disease.
- physiology : Herpesvirus 4, Human, Molecular Mimicry.
- virology : Parkinson Disease.
- Amino Acid Sequence, Animals, Humans, Molecular Sequence Data.
Abstract
Current concepts regarding the pathogenesis of Parkinson's disease support a model whereby environmental factors conspire with a permissive genetic background to initiate the disease. The identity of the responsible environmental trigger has remained elusive. There is incontrovertible evidence that aggregation of the neuronal protein alpha-synuclein is central to disease pathogenesis. A novel hypothesis of Parkinson's pathogenesis, articulated by Braak and colleagues, implicates a pathogen acting in the olfactory mucosa and gastrointestinal tract as the inciting agent. In this point-of-view article, we hypothesize that α-synuclein aggregation in Parkinson's disease is an Epstein-Barr virus (EBV)-induced autoimmune phenomenon. Specifically, we have shown evidence for molecular mimicry between the C-terminal region of α-synuclein and a repeat region in the latent membrane protein 1 encoded by EBV. We hypothesize that, in genetically-susceptible individuals, anti-EBV latent membrane protein antibodies targeting the critical repeat region cross react with the homologous epitope on α-synuclein and induce its oligomerization. Consistent with the Braak's proposed pattern of spread, we contend that axon terminals in the lamina propria of the gut are among the initial targets, with subsequent spread of pathology to the CNS. While at this time, we can only provide evidence from the literature and preliminary findings from our own laboratory, we hope that our hypothesis will stimulate the development of tractable experimental systems that can be exploited to test it. Further support for an EBV-induced immune pathogenesis for Parkinson's disease could have profound therapeutic implications.
DOI: 10.1016/j.parkreldis.2014.02.031
PubMed: 24726430
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000728
- to stream PubMed, to step Curation: 000728
- to stream PubMed, to step Checkpoint: 000728
- to stream Ncbi, to step Merge: 001725
- to stream Ncbi, to step Curation: 001725
- to stream Ncbi, to step Checkpoint: 001725
- to stream Main, to step Merge: 000A47
- to stream Main, to step Curation: 000A44
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.</title><author><name sortKey="Woulfe, John M" sort="Woulfe, John M" uniqKey="Woulfe J" first="John M" last="Woulfe">John M. Woulfe</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada. Electronic address: jwoulfe@ottawahospital.on.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Gray, Madison T" sort="Gray, Madison T" uniqKey="Gray M" first="Madison T" last="Gray">Madison T. Gray</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Gray, Douglas A" sort="Gray, Douglas A" uniqKey="Gray D" first="Douglas A" last="Gray">Douglas A. Gray</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Munoz, David G" sort="Munoz, David G" uniqKey="Munoz D" first="David G" last="Munoz">David G. Munoz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, St. Michael's Hospital, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, St. Michael's Hospital, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Middeldorp, Jaap M" sort="Middeldorp, Jaap M" uniqKey="Middeldorp J" first="Jaap M" last="Middeldorp">Jaap M. Middeldorp</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, VU Medical Center, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Pathology, VU Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24726430</idno><idno type="pmid">24726430</idno><idno type="doi">10.1016/j.parkreldis.2014.02.031</idno><idno type="wicri:Area/PubMed/Corpus">000728</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000728</idno><idno type="wicri:Area/PubMed/Curation">000728</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000728</idno><idno type="wicri:Area/PubMed/Checkpoint">000728</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000728</idno><idno type="wicri:Area/Ncbi/Merge">001725</idno><idno type="wicri:Area/Ncbi/Curation">001725</idno><idno type="wicri:Area/Ncbi/Checkpoint">001725</idno><idno type="wicri:Area/Main/Merge">000A47</idno><idno type="wicri:Area/Main/Curation">000A44</idno><idno type="wicri:Area/Main/Exploration">000A44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.</title><author><name sortKey="Woulfe, John M" sort="Woulfe, John M" uniqKey="Woulfe J" first="John M" last="Woulfe">John M. Woulfe</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada. Electronic address: jwoulfe@ottawahospital.on.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Gray, Madison T" sort="Gray, Madison T" uniqKey="Gray M" first="Madison T" last="Gray">Madison T. Gray</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Gray, Douglas A" sort="Gray, Douglas A" uniqKey="Gray D" first="Douglas A" last="Gray">Douglas A. Gray</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa</wicri:regionArea><wicri:noRegion>Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Munoz, David G" sort="Munoz, David G" uniqKey="Munoz D" first="David G" last="Munoz">David G. Munoz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, St. Michael's Hospital, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, St. Michael's Hospital, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Middeldorp, Jaap M" sort="Middeldorp, Jaap M" uniqKey="Middeldorp J" first="Jaap M" last="Middeldorp">Jaap M. Middeldorp</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, VU Medical Center, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Pathology, VU Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Herpesvirus 4, Human (physiology)</term><term>Humans</term><term>Molecular Mimicry (physiology)</term><term>Molecular Sequence Data</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (virology)</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Herpesvirus 4, Human</term><term>Molecular Mimicry</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Humans</term><term>Molecular Sequence Data</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current concepts regarding the pathogenesis of Parkinson's disease support a model whereby environmental factors conspire with a permissive genetic background to initiate the disease. The identity of the responsible environmental trigger has remained elusive. There is incontrovertible evidence that aggregation of the neuronal protein alpha-synuclein is central to disease pathogenesis. A novel hypothesis of Parkinson's pathogenesis, articulated by Braak and colleagues, implicates a pathogen acting in the olfactory mucosa and gastrointestinal tract as the inciting agent. In this point-of-view article, we hypothesize that α-synuclein aggregation in Parkinson's disease is an Epstein-Barr virus (EBV)-induced autoimmune phenomenon. Specifically, we have shown evidence for molecular mimicry between the C-terminal region of α-synuclein and a repeat region in the latent membrane protein 1 encoded by EBV. We hypothesize that, in genetically-susceptible individuals, anti-EBV latent membrane protein antibodies targeting the critical repeat region cross react with the homologous epitope on α-synuclein and induce its oligomerization. Consistent with the Braak's proposed pattern of spread, we contend that axon terminals in the lamina propria of the gut are among the initial targets, with subsequent spread of pathology to the CNS. While at this time, we can only provide evidence from the literature and preliminary findings from our own laboratory, we hope that our hypothesis will stimulate the development of tractable experimental systems that can be exploited to test it. Further support for an EBV-induced immune pathogenesis for Parkinson's disease could have profound therapeutic implications.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Woulfe, John M" sort="Woulfe, John M" uniqKey="Woulfe J" first="John M" last="Woulfe">John M. Woulfe</name></noRegion><name sortKey="Gray, Douglas A" sort="Gray, Douglas A" uniqKey="Gray D" first="Douglas A" last="Gray">Douglas A. Gray</name><name sortKey="Gray, Madison T" sort="Gray, Madison T" uniqKey="Gray M" first="Madison T" last="Gray">Madison T. Gray</name><name sortKey="Munoz, David G" sort="Munoz, David G" uniqKey="Munoz D" first="David G" last="Munoz">David G. Munoz</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Middeldorp, Jaap M" sort="Middeldorp, Jaap M" uniqKey="Middeldorp J" first="Jaap M" last="Middeldorp">Jaap M. Middeldorp</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24726430
|texte= Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24726430" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |